Systematic review: non-invasive prognostic tests for primary sclerosing cholangitis
- PMID: 33608929
- DOI: 10.1111/apt.16296
Systematic review: non-invasive prognostic tests for primary sclerosing cholangitis
Abstract
Background: Several prognostic tests for primary sclerosing cholangitis (PSC) have been developed, including biochemical models, elastography and magnetic resonance imaging scores.
Aim: To conduct a systematic review of non-invasive prognostic tests for PSC.
Methods: A systematic review was conducted from 1987 to 2020 of blood tests, biochemical models, elastography and imaging scores associated with outcomes in PSC.
Results: Forty studies of prognostic tests that collectively included 16 094 subjects with PSC were reviewed, of which 26 studies of non-invasive tests including 13 759 subjects with PSC were included. Normalisation or reduction of alkaline phosphatase with or without therapy was associated with transplant-free survival and reduced risk of hepatobiliary cancers but cut-off values for alkaline phosphatase were not consistent among studies. The most studied prognostic biochemical model was the Mayo Risk Score (MRS) evaluated in 18 studies with a c-statistic from 0.63 to 0.85 for clinical outcomes. One study demonstrated that the UK-PSC score outperforms MRS for predicting clinical outcomes with a c-statistics of 0.81and 0.75 respectively. A transient elastography score greater than 11.1 kPa is associated with survival and liver-related complications. The Anali score, derived from specific MRI and MRCP features, is associated with the development of cholangiocarcinoma and decompensated cirrhosis. Promising prognostic models include the enhanced liver fibrosis (ELF) score, ELF test and PREsTo scores.
Conclusion: MRS is the most studied prognostic score for clinical outcomes in PSC but the UK-PSC score and PREsTo have better test performance. Further studies comparing MRS to UK-PSC score, PREsTo or ELF with elastography or imaging-based scores are warranted.
© 2021 John Wiley & Sons Ltd.
Comment in
-
Letter: the use of magnetic resonance scores (Anali) for risk stratification in PSC-authors' reply.Aliment Pharmacol Ther. 2021 Jun;53(12):1331. doi: 10.1111/apt.16397. Aliment Pharmacol Ther. 2021. PMID: 34029410 No abstract available.
-
Letter: the use of magnetic resonance scores (Anali) for risk stratification in PSC.Aliment Pharmacol Ther. 2021 Jun;53(12):1329-1330. doi: 10.1111/apt.16378. Aliment Pharmacol Ther. 2021. PMID: 34029414 No abstract available.
References
REFERENCES
-
- Charatcharoenwitthaya P, Lindor KD. Primary sclerosing cholangitis: patients with a rising alkaline phosphatase at annual follow-up. Clin Gastroenterol Hepatol. 2007;5:32-36.
-
- Boonstra K, Weersma RK, van Erpecum KJ, et al. Population-based epidemiology, malignancy risk and outcome of primary sclerosing cholangitis. Hepatology. 2013;58(6):2045-2055.
-
- Dyson JK, Beuers U, Jones DEJ, et al. Primary sclerosing cholangitis. Lancet. 2018;391:2547-2559.
-
- Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Systematic Reviews. 2015;4:1-9.
-
- Moons KGM, Wolff RF, Riley RD, et al. PROBAST: a tool to assess risk of bias and applicability of prediction model studies: explanation and elaboration. Ann Intern Med. 2019;170:51-58.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical